Published: September 28, 2012
CAMBRIDGE, Mass. (September 28, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced the appointment of Bill D’Agostino as Senior Director of Manufacturing & Engineering. An executive leader focused on rapid market growth, Mr. D’Agostino joins InVivo following fifteen years at Covidien and, most recently, seven years at Angiotech Pharmaceuticals as Vice President, Engineering. In his career to date, Mr. D’Agostino has launched more than 100 new polymer products including families of biodegradable sutures. Mr. D’Agostino is a seasoned professional in medical devices and pharmaceutical […]View Article
Published: September 27, 2012
CAMBRIDGE, Mass. (September 27, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced that CEO Frank Reynolds is scheduled to present at the 2012 Aegis Healthcare Conference to be held September 27-29, 2012 at The Wynn, Las Vegas. The Company’s presentation will be on Friday, September 28th at 9:30 a.m. PDT (12:30 pm EDT). About the Neuro-Spinal Scaffold Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts as a physical substrate for nerve […]View Article
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.